Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Carmichael

Showing results (241-250 of 243) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 243 results.
The British Journal of Dermatology|October 14, 2014
A U.K. multicentre audit of the assessment and management of psoriasis in childrenM L Lam, E Burden-Teh, S M Taibjee, et al.
The British Journal of Dermatology|January 21, 2015
How are we using systemic drugs to treat psoriasis in children? An insight into current clinical U.K. practiceE Burden-Teh, M L Lam, S M Taibjee, et al.
The Lancet. Oncology|May 9, 2017
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Helen C Howard, et al.
Pageof 25

Showing results (241-250 of 243) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 243 results.
The British Journal of Dermatology|October 14, 2014
A U.K. multicentre audit of the assessment and management of psoriasis in childrenM L Lam, E Burden-Teh, S M Taibjee, et al.
The British Journal of Dermatology|January 21, 2015
How are we using systemic drugs to treat psoriasis in children? An insight into current clinical U.K. practiceE Burden-Teh, M L Lam, S M Taibjee, et al.
The Lancet. Oncology|May 9, 2017
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Helen C Howard, et al.
Pageof 25